Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer

Rahib, 2014, Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States, Cancer Res, 74, 2913, 10.1158/0008-5472.CAN-14-0155 Conroy, 2011, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, 364, 1817, 10.1056/NEJMoa1011923 von Hoff, 2013, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, N Engl J Med, 369, 1691, 10.1056/NEJMoa1304369 Aguirre, 2018, Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine, Cancer Discov, 8, 1096, 10.1158/2159-8290.CD-18-0275 Raphael, 2017, Integrated genomic characterization of pancreatic ductal adenocarcinoma, Cancer Cell, 32, 185, 10.1016/j.ccell.2017.07.007 Aung, 2018, Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial, Clin Cancer Res, 24, 1344, 10.1158/1078-0432.CCR-17-2994 Waddell, 2015, Whole genomes redefine the mutational landscape of pancreatic cancer, Nature, 518, 495, 10.1038/nature14169 Golan, 2019, Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer, N Engl J Med, 381, 317, 10.1056/NEJMoa1903387 Kindler, 2022, Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer, J Clin Oncol, 40, 3929, 10.1200/JCO.21.01604 O’Reilly, 2020, Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation, J Clin Oncol, 38, 1378, 10.1200/JCO.19.02931 Drilon, 2018, Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children, N Engl J Med, 378, 731, 10.1056/NEJMoa1714448 O’Reilly, 2019, Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion, Ann Oncol, 30, viii36, 10.1093/annonc/mdz385 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, 372, 2509, 10.1056/NEJMoa1500596 Philip, 2022, Molecular characterization of KRAS wild type tumors in patients with pancreatic adenocarcinoma, Clin Cancer Res, 28, 2704, 10.1158/1078-0432.CCR-21-3581 Umemoto, 2022, The molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling, J Natl Cancer Inst, 114(9), 1279, 10.1093/jnci/djac106 Heining, 2018, NRG1 fusions in KRAS wild-type pancreatic cancer, Cancer Discov, 8, 1087, 10.1158/2159-8290.CD-18-0036 Pishvaian, 2020, Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial, Lancet Oncol, 21, 508, 10.1016/S1470-2045(20)30074-7 Horak, 2021, Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers, Cancer Discov, 11, 2780, 10.1158/2159-8290.CD-21-0126 Allen, 2023, Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature, J Clin Pathol, 76, 158, 10.1136/jclinpath-2021-207781 Skoulidis, 2021, Sotorasib for lung cancers with KRAS p.G12C mutation, N Engl J Med, 384, 2371, 10.1056/NEJMoa2103695 Jänne, 2022, Adagrasib in non–small-cell lung cancer harboring a KRASG12C mutation, N Engl J Med, 387, 120, 10.1056/NEJMoa2204619 Strickler, 2023, Sotorasib in KRAS p.G12C–mutated advanced pancreatic cancer, N Engl J Med, 388, 33, 10.1056/NEJMoa2208470 Nassar, 2021, Distribution of KRASG12C somatic mutations across race, sex, and cancer type, N Engl J Med, 384, 185, 10.1056/NEJMc2030638 Koltun E, Cregg J, Rice MA, et al. Abstract 1260: first-in-class, orally bioavailable KRASG12V (ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRASG12V mutant cancers. Experimental and Molecular Therapeutics. Proceedings of the American Association for Cancer Research Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021. Philadelphia, PA: American Association for Cancer Research; 2021(81):1260. https://doi.org/10.1158/1538-7445.AM2021-1260. Hallin, 2022, Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor, Nat Med, 28, 2171, 10.1038/s41591-022-02007-7 Cobain, 2021, Assessment of clinical benefit of integrative genomic profiling in advanced solid tumors, JAMA Oncol, 7, 523 Flaherty, 2020, Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH), J Clin Oncol, 38, 3883, 10.1200/JCO.19.03010